The research team, led by investigators at Sichuan Provincial People’s Hospital in Chengdu, China, focused on sulfide:quinone oxidoreductase (SQOR), a flavoprotein embedded in the inner mitochondrial membrane. SQOR catalyzes the first committed step of hydrogen sulfide (H₂S) oxidation and transfers the resulting electrons to coenzyme Q (CoQ), generating the reduced antioxidant form CoQH₂. This biochemical position makes SQOR a plausible link between hypoxic metabolic adaptation, CoQH₂ availability, and suppression of lipid peroxidation, yet its role in pancreatic cancer had remained undefined.

Using a tissue microarray from 102 patients with PDAC, the researchers found that SQOR protein abundance showed moderate positive associations with the hypoxia markers carbonic anhydrase IX (CAIX) and hypoxia-inducible factor 1α (HIF-1α), with Spearman correlation coefficients of 0.473 and 0.438 respectively. Conversely, SQOR levels were inversely associated with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation, with a correlation coefficient of −0.465. Higher SQOR abundance was also associated with shorter overall survival after multivariable adjustment for GPX4 and FSP1, yielding an adjusted hazard ratio of 1.87.

Mechanistic experiments in PANC-1 and MIA PaCa-2 cells revealed that hypoxia increased SQOR expression and shifted the CoQH₂/total CoQ ratio upward by approximately 1.6-fold at 24 hours, while suppressing lipid peroxidation. These effects required SQOR catalytic activity rather than protein abundance alone, as a catalytically inactive mutant phenocopied SQOR knockdown. Electron-donor testing implicated hydrogen sulfide more strongly than selenium metabolism under the tested conditions, with H₂S donors increasing the reduced CoQ fraction in a dose-dependent manner and inhibition of the H₂S-producing enzymes CBS and CSE blunting the hypoxia-associated CoQ shift.

Lipidomic profiling showed that SQOR loss increased relative signals annotated as oxidized arachidonoyl- and adrenoyl-phosphatidylethanolamines, lipid species directly implicated as proximal ferroptotic death signals. Pathway-epistasis experiments demonstrated that SQOR loss synergized with inhibition of GPX4, FSP1, and DHODH, supporting a nonredundant contribution to ferroptosis control. Death-mode rescue assays showed that ferroptosis-directed agents provided substantially greater protection than a caspase inhibitor, consistent with a substantial ferroptotic contribution to the observed viability loss.

Therapeutic relevance was evaluated in gemcitabine-resistant cell lines, eight patient-derived organoid lines, and xenograft models. Gemcitabine-resistant cells showed approximately 2.8-fold higher SQOR protein, a rise in the CoQH₂/total CoQ ratio from about 27 percent to 49 percent, and baseline lipid ROS at roughly half the parental level. Combining a putative SQOR inhibitor with ferroptosis induction lowered gemcitabine IC₅₀ values in resistant models by six- to sevenfold relative to untreated resistant cells, though residual resistance remained 1.9- to 2.0-fold above parental sensitivity. In patient-derived organoids, the four SQOR-high lines showed paired viability reductions of approximately 46 to 52 percentage points when the SQOR inhibitor was added to gemcitabine, whereas the SQOR-low lines showed smaller, heterogeneous changes.

In xenograft models, the combination treatment reduced day-28 tumor volume and terminal tumor weight relative to gemcitabine alone, and prolonged survival in an independent cohort, with median survival extending from 35 days with gemcitabine to 49 days with the combination. However, tumor regression was not observed, and these efficacy endpoints alone do not establish SQOR target engagement or ferroptotic tumor-cell death in vivo.

The authors emphasize that the tissue correlations are associative and do not establish that hypoxia suppresses lipid peroxidation through SQOR in patients. The retrospective single-center cohort, the use of CAIX and HIF-1α staining rather than direct oxygen measurements, and the cross-sectional nature of the H-scores limit claims about temporal ordering and causal mediation. The exploratory mixed response endpoint, which combines radiological and biochemical criteria, is treated as hypothesis-generating rather than a validated clinical measure.

These findings support further preclinical evaluation of SQOR-directed strategies to improve gemcitabine sensitivity in PDAC. The SQOR–CoQ axis adds a mitochondrial sulfur-oxidation component to the layered ferroptosis-defense network, positioning it alongside established pathways involving GPX4, FSP1, and DHODH. Prospective clinical studies, broader genetic backgrounds, continuous-marker validation, and pharmacologically characterized SQOR interventions will be needed to determine whether this axis can be translated into a clinically actionable therapeutic strategy for patients with pancreatic cancer.

The connection between hydrogen sulfide metabolism and cancer cell survival has attracted growing attention in recent years, and the present study adds an important dimension to this emerging field. Hydrogen sulfide is often thought of as a toxic environmental gas, but it is also produced endogenously by mammalian enzymes, most notably cystathionine beta-synthase and cystathionine gamma-lyase, which operate in the transsulfuration pathway that branches off the methionine cycle. Under physiological conditions, H₂S acts as a signaling molecule involved in vascular tone, oxygen sensing, and cellular stress responses. Because mitochondria are the principal site of sulfide oxidation, the clearance of this gas is tightly coupled to the respiratory chain, and SQOR sits at the entry point of that clearance pathway. By transferring electrons from sulfide onto coenzyme Q, SQOR effectively converts a potentially damaging molecule into a source of reducing equivalents, and the new findings suggest that pancreatic cancer cells exploit this reaction to keep their mitochondrial membranes in a reduced, peroxidation-resistant state.

The coenzyme Q pool occupies a central position in this scheme because it serves multiple masters simultaneously. CoQ accepts electrons from complex I and complex II during oxidative phosphorylation, from dihydroorotate dehydrogenase during pyrimidine biosynthesis, and from sulfide oxidation through SQOR. The reduced form, CoQH₂, is itself a lipid-soluble radical-trapping antioxidant that can terminate lipid peroxidation chain reactions directly in membranes. This dual role explains why the same pool that fuels respiration can also suppress ferroptosis, and why the ferroptosis defenses mediated by FSP1 at the plasma membrane and DHODH in mitochondria both converge on CoQ reduction. The study’s epistasis experiments, showing that SQOR loss synergizes with inhibition of all three established defense systems, are consistent with this picture of partially independent but functionally overlapping layers of protection, each buffering lipid peroxides in a different cellular compartment.

The lipidomic observations deserve particular attention in this context. Phosphatidylethanolamines bearing polyunsaturated fatty acyl chains such as arachidonate are widely regarded as preferred substrates for the oxidative reactions that drive ferroptosis, and their oxidized products are among the most frequently cited death signals in the field. The finding that SQOR loss preferentially increased signals annotated as oxidized arachidonoyl- and adrenoyl-phosphatidylethanolamines therefore links the mitochondrial redox state to the specific molecular species most closely associated with ferroptotic execution. It is worth noting, as the authors do, that these are relative signals from untargeted lipidomics, and targeted validation of the individual oxidized species would strengthen the mechanistic chain from enzyme activity to membrane chemistry.

The hypoxic biology of pancreatic tumors provides a plausible rationale for why this pathway might be selected for during tumor evolution. Direct oxygen electrode measurements in human pancreatic cancers have documented some of the lowest tumor oxygen tensions recorded among solid malignancies, and the dense desmoplastic stroma further limits perfusion and drug penetration. Under such conditions, conventional mitochondrial respiration is constrained, and cancer cells must rewire their redox metabolism to survive. Inducing a sulfide-dependent route of CoQ reduction would allow cells to maintain antioxidant capacity even when electron flow through the canonical respiratory chain is limited by oxygen availability. The observed correlation between SQOR and HIF-1α, the master transcriptional regulator of the hypoxic response, fits this adaptive logic, although the study’s cross-sectional design cannot resolve whether hypoxia drives SQOR expression in patients or whether the two simply co-occur as markers of aggressive disease.

The therapeutic implications hinge on several caveats that the authors handle with appropriate care. The SQOR inhibitor used in the preclinical experiments is described as putative, meaning its selectivity, potency, and pharmacokinetic properties have not been fully characterized, and off-target effects cannot be excluded. The combination strategy lowered gemcitabine IC₅₀ values in resistant models but did not restore full parental sensitivity, indicating that SQOR-directed ferroptosis priming is a partial rather than complete reversal of the resistant phenotype. Residual resistance likely reflects the many other mechanisms by which pancreatic cancer cells evade chemotherapy, including impaired drug uptake, stromal barriers, and parallel survival pathways. The xenograft results, while encouraging, showed growth delay rather than regression, a pattern typical of cytostatic combinations in early preclinical testing.

From a broader perspective, the study contributes to a growing recognition that ferroptosis sensitivity is not governed by a single switch but by a layered network whose components can be independently tuned by metabolic context. Hypoxia, sulfur amino acid availability, selenium status, and membrane lipid composition all feed into this network, and different tumors may rely on different combinations of defenses. The demonstration that a catalytically inactive SQOR mutant phenocopied knockdown is particularly valuable, because it establishes that the relevant function is enzymatic rather than structural, which is a prerequisite for inhibitor-based therapeutic strategies. Future work will need to identify whether SQOR expression can be used as a predictive biomarker to select patients most likely to benefit from ferroptosis-inducing combinations, and whether pharmacological SQOR inhibition can be achieved safely given the enzyme’s normal role in sulfide detoxification. If those questions can be answered, the SQOR–CoQ axis may offer a way to convert one of pancreatic cancer’s most stubborn microenvironmental features, its profound hypoxia, from a shield against therapy into a therapeutic vulnerability.

Subject of Research: Hypoxia-induced sulfide:quinone oxidoreductase suppresses ferroptosis and promotes gemcitabine resistance through mitochondrial coenzyme Q reduction in pancreatic ductal adenocarcinoma

Article Title: Hypoxia-induced sulfide:quinone oxidoreductase suppresses ferroptosis and promotes gemcitabine resistance through mitochondrial coenzyme Q reduction in pancreatic ductal adenocarcinoma

Article References: Huang, G., An, X., Yuan, T., & Liao, D. (2026). Hypoxia-induced sulfide:quinone oxidoreductase suppresses ferroptosis and promotes gemcitabine resistance through mitochondrial coenzyme Q reduction in pancreatic ductal adenocarcinoma. Frontiers in Cell and Developmental Biology, 14, 1971375. https://doi.org/10.3389/fcell.2026.1971375

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1971375

Keywords: SQOR, ferroptosis, pancreatic cancer, gemcitabine resistance, hypoxia, coenzyme Q, Hypoxia-induced, sulfide, quinone, oxidoreductase, suppresses, promotes

RRM2 is not an unfamiliar name in oncology. As the regulatory subunit of ribonucleotide reductase, the enzyme complex that converts ribonucleotides into the deoxyribonucleotides needed for DNA synthesis and repair, it is essential for proliferating cells and has previously been associated with aggressive disease in several tumor types. What makes the new work distinctive is its attempt to connect RRM2 to lipid biology and to chemotherapy response within the same framework, using a combination of bulk transcriptomic data, clinical survival information, single-cell RNA sequencing, tissue-level protein evidence, and a battery of laboratory experiments in pancreatic cancer cell lines and mouse models.

The bioinformatic arm of the study established the clinical backdrop. RRM2 was found to be upregulated in pancreatic ductal adenocarcinoma compared with non-tumor tissue, and elevated expression tracked with unfavorable clinical characteristics and shorter overall survival. When the researchers examined the molecular programs that RRM2 expression correlated with, they found a signature that went well beyond simple proliferation. RRM2 levels were associated with hypoxia, epithelial-mesenchymal transition, and, notably, fatty-acid-metabolism-related programs, with correlations to genes such as FASN, the enzyme that manufactures fatty acids from scratch; ACSL4, which activates fatty acids for further metabolism; PLIN2, a marker of lipid droplets; SCD, which desaturates fatty acids; and SREBF1, the master transcription factor controlling the lipogenic program.

That correlation set the stage for the study’s central experiment. The team exposed PANC-1 and SW1990 pancreatic cancer cells to palmitate, a saturated fatty acid, to mimic the lipid-rich conditions that pancreatic tumors often encounter, and then tested how the cells responded to gemcitabine. The result was striking: palmitate exposure increased the IC50 value of gemcitabine, meaning that substantially more drug was required to achieve the same killing effect. Under these lipid-stressed conditions, the cells adopted a recognizable phenotype characterized by high RRM2, high thymidylate synthase (TYMS), low DCK, the enzyme that activates gemcitabine inside the cell, high FASN, high ACSL4, and elevated PCNA, a proliferation marker. Lipid-droplet accumulation, visualized with BODIPY 493/503 staining, accompanied this shift.

To test whether RRM2 was merely a passenger or an active participant in this drug-tolerant state, the researchers depleted it using small interfering RNA. The consequences were broad. RRM2 knockdown reduced the gemcitabine IC50, meaning the cells became more sensitive to the drug. It also suppressed lipid accumulation and proliferative markers, and, importantly, restored expression of DCK, the very enzyme that pancreatic tumors often lose to deactivate gemcitabine. At the same time, the treated cells accumulated more γ-H2AX, a molecular beacon for DNA double-strand breaks, and showed increased apoptosis. When the team re-expressed RRM2 in the depleted cells, these effects were partially reversed, supporting a causal role for the gene rather than an off-target artifact of the knockdown procedure.

The study then probed the mechanism linking RRM2 to fat metabolism. Because RRM2 is a nucleotide-metabolism protein, it cannot directly regulate lipid genes in the way a transcription factor would, so the investigators turned to SREBF1, the gene encoding SREBP1, the transcriptional regulator of fatty-acid synthesis. In a series of reciprocal experiments, they showed that re-expressing SREBF1 in RRM2-depleted cells partially restored lipid accumulation, FASN expression, nuclear SREBP1 protein, and tolerance to gemcitabine. In other words, the lipogenic arm of the phenotype could be rescued independently of RRM2 itself, suggesting that RRM2 and the SREBP1/FASN axis functionally cooperate to produce the gemcitabine-tolerant state rather than one simply causing the other in a linear chain.

Supportive evidence came from an in vivo model using mice fed a high-fat diet, designed to reproduce the metabolic context in which many patients with pancreatic cancer live. In these animals, the high-fat diet attenuated the antitumor activity of gemcitabine, echoing the in vitro finding that lipid abundance blunts drug efficacy. Adding RRM2-targeting siRNA to the high-fat diet plus gemcitabine regimen further reduced xenograft growth and lowered expression of FASN, TYMS, and the proliferation marker Ki-67, while increasing tumor necrosis and γ-H2AX accumulation. The authors are careful to characterize this as supportive rather than definitive evidence of therapeutic benefit, an appropriate level of caution for a xenograft experiment that has not yet been replicated in more faithful models or in patients.

The significance of the work lies in how it reframes gemcitabine resistance. Classic explanations have centered on the drug’s own pathway: insufficient uptake, reduced activation by DCK, accelerated catabolism, or elevated RRM2 itself, which allows cells to out-replicate the drug’s damage by maintaining deoxyribonucleotide pools. The new study does not overturn that framework but widens it, proposing that metabolic adaptation, specifically the SREBP1/FASN-driven accumulation of lipid droplets, operates in concert with nucleotide-metabolism changes to create a state in which the tumor is simultaneously better at copying its DNA and better insulated from metabolic stress. A cell in that state is harder to kill with a drug that works by masquerading as a DNA building block.

There are also translational implications, though they come with caveats. If RRM2 depletion genuinely sensitizes tumors to gemcitabine under lipid-rich conditions, then RRM2 inhibitors, some of which have been explored clinically, or dietary and pharmacological interventions that limit lipid availability could theoretically improve chemotherapy response. The study’s own data temper such optimism: the SREBF1 rescue was partial, the in vivo combination experiment was supportive rather than definitive, and the gap between xenografts and human disease in pancreatic cancer is notoriously wide. Single-agent strategies targeting RRM2 have historically struggled with toxicity, because normal proliferating tissues also depend on ribonucleotide reductase.

What the study does provide is a well-integrated map of a phenomenon that clinicians observe daily: patients with pancreatic cancer respond variably to gemcitabine, and metabolic context appears to matter. By tying RRM2 expression to survival, to lipid-metabolism gene programs, and to measurable changes in drug sensitivity, DNA damage, and apoptosis in controlled experiments, the Chongqing-based team has generated a testable hypothesis about how tumor metabolism and chemotherapy resistance interlock. The next steps, validating the RRM2–SREBP1/FASN axis in patient-derived models and determining whether disrupting lipid remodeling can restore gemcitabine efficacy in the clinic, will determine whether this bioinformatic lead matures into a genuine therapeutic strategy for one of medicine’s most stubborn cancers.

Subject of Research: The role of RRM2 in linking lipid metabolic remodeling and gemcitabine resistance in pancreatic ductal adenocarcinoma

Article Title: Integrated bioinformatics identifies RRM2 as a lipid remodeling- and gemcitabine response-related gene in pancreatic cancer

Article References: Song, N., Wu, Y., Wu, Y., Huang, X., & Wang, J. (2026). Integrated bioinformatics identifies RRM2 as a lipid remodeling- and gemcitabine response-related gene in pancreatic cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-16948-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16948-6

Keywords: pancreatic cancer, RRM2, gemcitabine resistance, lipid metabolism, SREBF1, FASN, nucleotide metabolism, chemotherapy resistance, bioinformatics, fatty acid synthesis, apoptosis, BMC Cancer

USP16 belongs to a large family of deubiquitinating enzymes, proteases that snip ubiquitin tags off target proteins. Ubiquitination is one of the cell’s principal mechanisms for marking proteins for destruction: when chains of ubiquitin molecules, particularly those linked through their lysine 48 residues, are attached to a protein, the proteasome recognizes the tag and degrades the cargo. Deubiquitinases reverse this process, rescuing proteins from degradation and thereby fine-tuning their abundance. In the new study, the researchers found that USP16 is markedly upregulated in gemcitabine-resistant pancreatic cancer specimens, and that elevated levels of the enzyme correlate with metastatic disease and poor patient prognosis, positioning USP16 as a potential biomarker of aggressive disease.

The functional experiments carried out by the team went beyond correlation. When the researchers silenced USP16 genetically or inhibited it pharmacologically, pancreatic cancer cells lost key malignant behaviors: proliferation slowed, invasive capacity diminished, and, critically, sensitivity to gemcitabine was restored. The same effects were reproduced in animal models, where USP16 suppression curbed tumor progression and re-sensitized tumors to chemotherapy. These results, the authors report, held both in vitro and in vivo, suggesting that USP16 is not merely a passenger mutation or a passive marker of aggressive disease but an active participant in maintaining the resistant phenotype.

The mechanistic heart of the paper lies in metabolism. Cancer cells famously favor glycolysis, the fermentation of glucose into lactate, even in the presence of abundant oxygen, a phenomenon known as the Warburg effect. This metabolic reprogramming supplies rapidly dividing tumors with biosynthetic building blocks and helps them survive environmental stress. The researchers demonstrated that USP16 promotes this glycolytic switch by stabilizing a transcription factor called Far Upstream Element Binding Protein 1, or FUBP1. Biochemical analysis showed that USP16 preferentially removes K48-linked polyubiquitin chains from FUBP1, shielding the protein from proteasomal destruction. With FUBP1 stabilized, pancreatic cancer cells accumulate higher levels of this transcription factor in the nucleus.

FUBP1, in turn, drives transcription of lactate dehydrogenase A, or LDHA, the enzyme that catalyzes the conversion of pyruvate to lactate, the final and defining step of anaerobic glycolysis. By enhancing FUBP1-dependent LDHA expression, USP16 effectively turns up the dial on lactate production, fueling the metabolic state that supports rapid proliferation and chemoresistance. The connection is biologically plausible: high glycolytic flux has been repeatedly linked to drug resistance in solid tumors, partly because glycolytic tumors maintain acidic, hypoxic microenvironments that blunt the efficacy of chemotherapeutic agents and promote survival signaling. The USP16-FUBP1-LDHA axis therefore offers a coherent explanation for how a single deubiquitinase can simultaneously promote metastatic behavior and undermine gemcitabine therapy.

Perhaps the most intricate portion of the study concerns how USP16 itself becomes overexpressed in pancreatic cancer in the first place. The researchers traced the excess USP16 to two upstream layers of regulation. The first involves N6-methyladenosine, or m6A, the most abundant internal chemical modification in messenger RNA. The methyltransferase-like 3 enzyme, METTL3, installs m6A marks on the USP16 transcript, and these modifications enhance the message’s translation or processing. The second layer involves Insulin-like Growth Factor 2 mRNA-Binding Protein 1, or IGF2BP1, a reader protein that recognizes m6A-modified transcripts and stabilizes them, preventing degradation. Together, METTL3-mediated methylation and IGF2BP1-dependent stabilization elevate USP16 protein levels in pancreatic cancer cells, setting the entire pathological cascade in motion.

This architecture, which the authors describe as a METTL3/IGF2BP1-USP16-FUBP1-LDHA regulatory axis, is notable because it links three major themes in contemporary cancer biology: epitranscriptomic regulation through RNA modifications, post-translational control through ubiquitination, and metabolic reprogramming through glycolysis. Each layer of the axis represents a potential point of therapeutic intervention, and the study’s demonstration that both genetic and pharmacological USP16 inhibition suppress tumor progression suggests that deubiquitinase inhibitors could form the basis of new combination strategies designed to be administered alongside gemcitabine.

The clinical implications are considerable. Gemcitabine resistance is one of the chief reasons pancreatic cancer has a five-year survival rate that remains among the lowest of any major cancer. If USP16 levels can be measured reliably in tumor biopsies, the enzyme could serve as a biomarker identifying patients likely to derive limited benefit from gemcitabine-based regimens, guiding clinicians toward alternative or intensified approaches. More ambitiously, if USP16 inhibitors can be developed with acceptable safety profiles, they might resensitize resistant tumors to existing chemotherapy, extending the usefulness of a drug that has been a workhorse in pancreatic oncology for decades. The study’s finding that pharmacological USP16 inhibition restored gemcitabine sensitivity in vivo provides an early proof of concept for that strategy.

Caveats remain, as they do with any preclinical study. The work was conducted in cell lines and animal models, and the translation of deubiquitinase inhibition into human therapy will require medicinal chemistry advances, since deubiquitinases share catalytic mechanisms that can make selective inhibition challenging. The authors also note that the published version is an early-release, peer-reviewed accepted manuscript subject to further editorial refinement. Nonetheless, the identification of a complete signaling axis, from RNA modification through protein stabilization to metabolic enzyme expression, gives researchers a detailed map of a resistance pathway that had remained poorly understood, and it adds USP16 to the growing list of deubiquitinating enzymes implicated in cancer metabolism.

For a disease that has seen painfully slow therapeutic progress, studies that illuminate the machinery of chemoresistance carry real weight. By showing how an m6A-modified, IGF2BP1-stabilized transcript elevates a deubiquitinase that in turn protects a transcription factor governing lactate metabolism, the research team has connected molecular layers that are usually studied in isolation. Whether targeting USP16 will ultimately improve outcomes for patients with pancreatic ductal adenocarcinoma will depend on the development of clinically viable inhibitors and appropriately designed trials, but the study establishes a clear, testable framework for attacking gemcitabine resistance at its metabolic roots, and it underscores how deeply the survival of this formidable cancer depends on the reprogramming of its energy economy.

Subject of Research: USP16-mediated glycolytic reprogramming and gemcitabine resistance in pancreatic ductal adenocarcinoma

Article Title: USP16 promotes pancreatic ductal adenocarcinoma progression and gemcitabine resistance through FUBP1/LDHA axis-mediated glycolysis

Article References: Dong, Y., Lin, C., Fang, H., Tan, Z., Lu, J., Liu, Z., Lai, S., & Wang, Y. (2026). USP16 promotes pancreatic ductal adenocarcinoma progression and gemcitabine resistance through FUBP1/LDHA axis-mediated glycolysis. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06466-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06466-w

Keywords: pancreatic ductal adenocarcinoma, USP16, deubiquitinase, FUBP1, LDHA, glycolysis, gemcitabine resistance, m6A modification, METTL3, IGF2BP1, cancer metabolism, chemoresistance

Ferroptosis is an iron-dependent, non-apoptotic form of cell death defined by the catastrophic accumulation of lipid peroxides in cellular membranes. Unlike apoptosis, which cancer cells frequently evade through well-characterized mutations, ferroptosis depends on the lipid composition of the cell, and one enzyme sits at the heart of that dependency: acyl-CoA synthetase long-chain family member 4, commonly abbreviated ACSL4. ACSL4 shapes the membrane pool of oxidizable polyunsaturated fatty acids, and cells with high ACSL4 levels are markedly more vulnerable to ferroptotic death. The new work demonstrates that pancreatic cancer cells actively destroy ACSL4 under hypoxic conditions, and that this destruction is orchestrated by an unexpected player drawn from the machinery of valine, an essential branched-chain amino acid.

The researchers began by comparing tumor samples from patients who responded to gemcitabine-based neoadjuvant chemotherapy with those from non-responders. Metabolomic and transcriptomic profiling revealed that valine, leucine, and isoleucine degradation was significantly enriched in non-responders, and within that pathway the gene encoding MMSDH, ALDH6A1, stood out for its association with poor treatment response and reduced disease-free survival. Transcription factor analysis traced elevated MMSDH expression to SP1, a transcription factor that binds the ALDH6A1 promoter in gemcitabine-resistant tumors, suggesting that the metabolic wiring of these cancers is rewired at the gene expression level before any drug ever enters the cell.

The mechanistic story then deepens in the oxygen-starved interiors of pancreatic tumors. Hypoxia, the researchers found, triggers an enzyme called GCN5 to install a lactyl group, a derivative of lactate, onto MMSDH at the amino acid lysine 113. This modification, known as lactylation, is part of a growing family of metabolite-driven protein modifications that have recently been shown to regulate DNA repair, chromatin biology, and now cancer metabolism. Lactylated MMSDH physically interacts with ACSL4 and, through its catalytic activity, generates propionyl-CoA, a short-chain acyl intermediate of valine catabolism. That propionyl-CoA is then handed to another acetyltransferase, KAT8, which uses it to attach a propionyl group to ACSL4 at lysine 606.

The consequences of this single chemical mark are profound. Propionylation at K606 repositions ACSL4 so that it binds HSC70, the cytosolic chaperone that recognizes the KFERQ-like targeting motifs required for chaperone-mediated autophagy, a selective degradation pathway in which individual proteins are unfolded and threaded into lysosomes. Once flagged in this way, ACSL4 is destroyed, its lipid-remodeling activity collapses, and the tumor cell becomes resistant to the lipid peroxidation that gemcitabine otherwise promotes. Using mass spectrometry, the team confirmed both the K113 lactylation on MMSDH and the K606 propionylation on ACSL4 in hypoxic pancreatic cancer cells, and showed that mutant versions of these proteins that cannot be modified fail to drive ACSL4 degradation or protect cells from ferroptotic death induced by gemcitabine, erastin, or RSL3.

Critically, the findings are not confined to cell culture. In an analysis of patient cohorts, tumors harboring high levels of MMSDH K113 lactylation and ACSL4 K606 propionylation displayed low ACSL4 protein, heightened ferroptosis resistance, and poor clinical response to neoadjuvant chemotherapy. Mouse xenograft experiments extended the picture: tumor cells engineered to express non-modifiable mutants of MMSDH or ACSL4 lost their protective shield and became acutely vulnerable to gemcitabine, while cells bearing the modification-enhancing wild-type enzymes grew aggressively even under low-oxygen conditions and responded poorly to treatment. The team also showed that the same axis operates in lung and ovarian cancer cell lines, hinting that MMSDH-mediated ACSL4 propionylation may be a broader mechanism of ferroptosis evasion across solid tumors.

Perhaps the most translational aspect of the study lies in two therapeutic strategies the authors developed to disrupt this axis. The first is dietary: because MMSDH is a valine catabolism enzyme that depends on valine-derived substrate to generate propionyl-CoA, restricting dietary valine in mice starved the pathway of its fuel. Combining valine-restricted diets with gemcitabine synergistically restored lipid peroxidation and suppressed tumor growth, notably without causing significant toxicity, weight loss, or metabolic distress in the animals. The second approach is pharmacological: the team designed cell-penetrating blocking peptides centered on the lactylated K113 sequence of MMSDH. A lead peptide disrupted the interaction between lactylated MMSDH and ACSL4, prevented ACSL4 propionylation and degradation, restored ferroptotic sensitivity, and markedly potentiated gemcitabine in both subcutaneous and orthotopic pancreatic tumor models while improving animal survival.

Beyond the immediate therapeutic implications, the study expands the conceptual map of how post-translational modifications couple cellular metabolism to cell fate. Amino acid catabolic enzymes are increasingly appreciated as moonlighting regulators of signaling and protein stability, and this work adds a new chapter by showing that a valine-processing enzyme can be co-opted by hypoxia-driven lactylation to flag a ferroptosis gatekeeper for lysosomal destruction. It also illustrates a chemical relay of remarkable economy: hypoxia produces lactate, lactate lactylates MMSDH, lactylated MMSDH produces propionyl-CoA from valine, and propionyl-CoA propionylates ACSL4, linking three metabolic programs, glycolysis, branched-chain amino acid catabolism, and lipid metabolism, into a single survival circuit. The authors’ clinical data suggest that MMSDH K113 lactylation and ACSL4 K606 propionylation may serve as biomarkers for predicting which pancreatic cancer patients will benefit from gemcitabine-based neoadjuvant regimens, potentially guiding treatment selection in a disease where therapeutic options remain painfully limited.

Challenges remain before this biology reaches the clinic. Blocking peptides must be optimized for delivery, stability, and specificity in humans, and dietary valine restriction will need careful evaluation in clinical trials, particularly given the catabolic state of many pancreatic cancer patients. Yet the study provides something pancreatic oncology has long needed: a mechanistically resolved, chemically validated, and clinically correlated explanation for why so many tumors shrug off chemotherapy, together with concrete tools to break that resistance. By exposing the GCN5-MMSDH-ACSL4 axis, the Zhejiang University team has turned a metabolic quirk of hypoxic tumor cells into a target, and in doing so opened a plausible path toward making ferroptosis-inducing chemotherapy a reality for one of medicine’s most intractable cancers.

Subject of Research: Hypoxia-driven MMSDH lactylation and ACSL4 propionylation as a mechanism of ferroptosis evasion and chemotherapy resistance in pancreatic ductal adenocarcinoma

Article Title: MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Article References: Zheng, P., Lin, Y., Zhang, M., Tang, Z., Qin, W., Xiao, M., Sun, X., Shen, Y., Hu, Z., Ru, S., Duan, Y., Dong, B., Wen, T., Li, M., Wu, H., Hou, Y., Ji, G., Wang, Z., Wu, X., … Xu, D. (2026). MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy. Nature Cancer. https://doi.org/10.1038/s43018-026-01236-w

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01236-w

Keywords: pancreatic ductal adenocarcinoma, ferroptosis, MMSDH, ACSL4, lactylation, propionylation, hypoxia, gemcitabine resistance, chaperone-mediated autophagy, valine metabolism, GCN5, KAT8